Wednesday, July 8, 2026

pharma · Hyperphagia · Bariatric Surgery · AARD

Ark Therapeutics

Arkana Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker AARD. Primary therapeutic focus areas include Hyperphagia, Bariatric Surgery, Obesity, Prader-Willi Syndrome, Aut

Boulder, USA HQ
2025 Founded
4 Employees
Public company Type
AARD · NYSE Ticker
Company details
Status
Public
HQ
Boulder, USA
Founded
2025
Employees
4
Programs
6
Drugs
5
Patents
7

Quick answer

Arkana Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker AARD. Primary therapeutic focus areas include Hyperphagia, Bariatric Surgery, Obesity, Prader-Willi Syndrome, Autism Spectrum Disorder. NovaPharmaNews links 6 clinical program(s), 1 drug profile(s), and 7 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (4), phase 3 (2).

Company snapshot

Arkana Therapeutics is developing innovative medicines for metabolic diseases by harnessing nature’s extreme biology. Arkana's approach to drug discovery leverages the natural biology of animals with extreme metabolic adaptations to uncover therapies that prevent and reverse metabolic diseases in humans. By following this evolutionarily-honed blueprint in nature, we are developing first-in-class t

  • 1 approved product(s) across US/EU regulatory metadata.
  • 6 active pipeline program(s) linked via ClinicalTrials.gov.
  • 7 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Ark Therapeutics. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Ark Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 6 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Ark Therapeutics.

  1. Clinical update

    Low Dose ARD-501 — Phase 2

  2. Clinical update

    Placebo — Phase 3

  3. Clinical update

    ARD-101 — Phase 3

  4. Clinical update

    ARD-101 — Phase 2

  5. Clinical update

    ARD-101 — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Ark Therapeutics?

    Arkana Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker AARD. Primary therapeutic focus areas include Hyperphagia, Bariatric Surgery, Obesity, Prader-Willi Syndrome, Autism Spectrum Disorder. NovaPharmaNews links 6 clinical progr

  • Is Ark Therapeutics publicly traded?

    Yes. Ark Therapeutics is listed with ticker AARD on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Ark Therapeutics develop or market?

    We link 5 drug profile(s) where Ark Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aardvark-therapeutics#company-drugs.

  • What are the latest developments for Ark Therapeutics?

    In the last 12 months our linked public records show 6 trial program update(s) and 4 US patent grant(s) tied to this profile.

  • What therapeutic areas does Ark Therapeutics focus on?

    Ark Therapeutics focuses on Hyperphagia, Bariatric Surgery, Obesity based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
11